A serial entrepreneur with decades of experience building value in biotech, Mark Bamforth has founded, built and sold three CDMOs. As CEO and Board Chair of Kincell Bio, Mark is leading the growth of the company as a preferred provider of cell therapy services.
In 2019, Mark founded Arranta Bio, an advanced therapeutics CDMO focused on the microbiome, plasmid and mRNA vaccines, which was sold to Recipharm in April 2022. Previously, he founded Brammer Bio, a best-in-class viral vector CDMO for cell and gene therapies that supported leading innovators and was acquired by Thermo Fisher Scientific in 2019. In 2010, he founded a biologics CDMO, Gallus BioPharmaceuticals, and acquired a world-class facility and team with a commercial supply agreement with Janssen, which was sold to DPx Holdings (Patheon) in 2014.
Mark spent 22 years at Genzyme, with nearly a decade as a corporate officer leading the Company’s 12-site global manufacturing operation and a pharmaceutical CMO unit. He serves on the boards of Continuus Pharma, Pneumagen, Enterobiotix and Entrepreneurial Scotland. Mark has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.
Bamforth serves on the boards of CONTINUUS Pharma, Enterobiotix, Inceptor Bio, Pneumagen, and Entrepreneurial Scotland. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.
